Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6 | $6 | $6 | $5 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $2 |
| Gross Profit | $4 | $4 | $4 | $3 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $2 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $3 |
| Operating Income | $1 | $1 | $1 | $0 |
| % Margin | 21.3% | 16.7% | 20.3% | 7.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$1 |
| Pre-Tax Income | $1 | $1 | $1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $1 | $1 | -$0 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| Weighted Avg Shares Out | 4 | 4 | 3 | 3 |
| Weighted Avg Shares Out Dil | 4 | 4 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $2 | $2 | $2 | $1 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |